Pfizer and Watson Health Announce Immuno-oncology Collaboration
December 01, 2016
Pfizer and Watson Health have announced a collaboration to help accelerate Pfizer’s research in immuno-oncology.
Pfizer will deploy Watson for Drug Discovery and customize the cloud-based cognitive tool to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.
Oncology researchers at Pfizer will use the tool to analyze massive volumes of disparate data sources, including licensed and publicly available dataas well as Pfizer’s proprietary data, a press release stated.
While the average researcher reads between 200 and 300 articles in a given year, the Watson for Drug Discovery tool "has ingested 25 million Medline abstracts, more than 1 million full-text medical journal articles, 4 million patents and is regularly updated," the release adds.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
